Biomarker-based methods for determining noncompliance in a prevention trial

Donna P Ankerst, Kathryn B. Gower, Phyllis J. Goodman, John J. Crowley, Ian M. Thompson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The Prostate Cancer Prevention Trial (PCPT) is a 7-year randomized trial of 18,000 men designed to test a daily dose of finasteride (5 mg/d) for the primary prevention of prostate cancer. Compliance is assessed every 6 months by determining the percentage of pills consumed since the previous visit. In addition, levels of 5α-dihydrotestosterone (DHT) are measured at yearly intervals in a random subset of 5% of participants in the trial as part of a substudy to investigate the potential of this biomarker for monitoring compliance. Motivated by this substudy, we outline three biomarker-based rules for monitoring compliance over time in prevention trials. We make comparisons among the rules using receiver operating characteristic curves. We illustrate the methods using the biomarker DHT in the PCPT substudy with pill counts as a gold standard, and in a simulation study under a hypothetical true gold standard. Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history.

Original languageEnglish (US)
Pages (from-to)675-685
Number of pages11
JournalControlled Clinical Trials
Volume23
Issue number6
DOIs
StatePublished - Dec 2002

Fingerprint

Biomarkers
Compliance
Prostatic Neoplasms
Dihydrotestosterone
Finasteride
Primary Prevention
ROC Curve
History

Keywords

  • 5α-dihydrotestosterone (DHT)
  • Pill counts
  • Prostate cancer
  • Sensitivity
  • Specificity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ankerst, D. P., Gower, K. B., Goodman, P. J., Crowley, J. J., & Thompson, I. M. (2002). Biomarker-based methods for determining noncompliance in a prevention trial. Controlled Clinical Trials, 23(6), 675-685. https://doi.org/10.1016/S0197-2456(02)00231-3

Biomarker-based methods for determining noncompliance in a prevention trial. / Ankerst, Donna P; Gower, Kathryn B.; Goodman, Phyllis J.; Crowley, John J.; Thompson, Ian M.

In: Controlled Clinical Trials, Vol. 23, No. 6, 12.2002, p. 675-685.

Research output: Contribution to journalArticle

Ankerst, DP, Gower, KB, Goodman, PJ, Crowley, JJ & Thompson, IM 2002, 'Biomarker-based methods for determining noncompliance in a prevention trial', Controlled Clinical Trials, vol. 23, no. 6, pp. 675-685. https://doi.org/10.1016/S0197-2456(02)00231-3
Ankerst, Donna P ; Gower, Kathryn B. ; Goodman, Phyllis J. ; Crowley, John J. ; Thompson, Ian M. / Biomarker-based methods for determining noncompliance in a prevention trial. In: Controlled Clinical Trials. 2002 ; Vol. 23, No. 6. pp. 675-685.
@article{9206a5fb94634dcf92565558538bad69,
title = "Biomarker-based methods for determining noncompliance in a prevention trial",
abstract = "The Prostate Cancer Prevention Trial (PCPT) is a 7-year randomized trial of 18,000 men designed to test a daily dose of finasteride (5 mg/d) for the primary prevention of prostate cancer. Compliance is assessed every 6 months by determining the percentage of pills consumed since the previous visit. In addition, levels of 5α-dihydrotestosterone (DHT) are measured at yearly intervals in a random subset of 5{\%} of participants in the trial as part of a substudy to investigate the potential of this biomarker for monitoring compliance. Motivated by this substudy, we outline three biomarker-based rules for monitoring compliance over time in prevention trials. We make comparisons among the rules using receiver operating characteristic curves. We illustrate the methods using the biomarker DHT in the PCPT substudy with pill counts as a gold standard, and in a simulation study under a hypothetical true gold standard. Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history.",
keywords = "5α-dihydrotestosterone (DHT), Pill counts, Prostate cancer, Sensitivity, Specificity",
author = "Ankerst, {Donna P} and Gower, {Kathryn B.} and Goodman, {Phyllis J.} and Crowley, {John J.} and Thompson, {Ian M.}",
year = "2002",
month = "12",
doi = "10.1016/S0197-2456(02)00231-3",
language = "English (US)",
volume = "23",
pages = "675--685",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Biomarker-based methods for determining noncompliance in a prevention trial

AU - Ankerst, Donna P

AU - Gower, Kathryn B.

AU - Goodman, Phyllis J.

AU - Crowley, John J.

AU - Thompson, Ian M.

PY - 2002/12

Y1 - 2002/12

N2 - The Prostate Cancer Prevention Trial (PCPT) is a 7-year randomized trial of 18,000 men designed to test a daily dose of finasteride (5 mg/d) for the primary prevention of prostate cancer. Compliance is assessed every 6 months by determining the percentage of pills consumed since the previous visit. In addition, levels of 5α-dihydrotestosterone (DHT) are measured at yearly intervals in a random subset of 5% of participants in the trial as part of a substudy to investigate the potential of this biomarker for monitoring compliance. Motivated by this substudy, we outline three biomarker-based rules for monitoring compliance over time in prevention trials. We make comparisons among the rules using receiver operating characteristic curves. We illustrate the methods using the biomarker DHT in the PCPT substudy with pill counts as a gold standard, and in a simulation study under a hypothetical true gold standard. Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history.

AB - The Prostate Cancer Prevention Trial (PCPT) is a 7-year randomized trial of 18,000 men designed to test a daily dose of finasteride (5 mg/d) for the primary prevention of prostate cancer. Compliance is assessed every 6 months by determining the percentage of pills consumed since the previous visit. In addition, levels of 5α-dihydrotestosterone (DHT) are measured at yearly intervals in a random subset of 5% of participants in the trial as part of a substudy to investigate the potential of this biomarker for monitoring compliance. Motivated by this substudy, we outline three biomarker-based rules for monitoring compliance over time in prevention trials. We make comparisons among the rules using receiver operating characteristic curves. We illustrate the methods using the biomarker DHT in the PCPT substudy with pill counts as a gold standard, and in a simulation study under a hypothetical true gold standard. Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history.

KW - 5α-dihydrotestosterone (DHT)

KW - Pill counts

KW - Prostate cancer

KW - Sensitivity

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=0036911515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036911515&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(02)00231-3

DO - 10.1016/S0197-2456(02)00231-3

M3 - Article

C2 - 12505245

AN - SCOPUS:0036911515

VL - 23

SP - 675

EP - 685

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 6

ER -